Effect of long-term valproic acid therapy on lipid profiles in paediatric patients with epilepsy: a meta-analysis
Fiche du document
2023
- handle: 10670/1.9cxg67
Cairn
Mots-clés
valproic acid total cholesterol (TC) low-density lipoprotein cholesterol (LDL-C) high-density lipoprotein cholesterol (HDL-C) triglycerides (TG)Sujets proches
CholesterinCiter ce document
Hong-Li Guo et al., « Effect of long-term valproic acid therapy on lipid profiles in paediatric patients with epilepsy: a meta-analysis », Epileptic Disorders, ID : 10670/1.9cxg67
Métriques
Partage / Export
Résumé
Objective Despite the potential role of valproic acid (VPA) in weight gain, the effects of VPA therapy on lipid profiles remain unclear. This study aimed to review the influence of VPA therapy on serum lipid profiles in children with epilepsy. Methods This meta-analysis was conducted on data from PubMed, Web of Science, Cochrane Library, and Embase databases. Case-controlled studies, which assessed the effects of VPA therapy on lipid profiles, were included. All outcomes were recorded as continuous variables, and the effect size was measured. Results VPA therapy was associated with a significant reduction in total cholesterol (mean difference [MD]=-6.34, 95% confidence interval [CI]: -12.30, -0.37, p=0.04) and low-density lipoprotein cholesterol levels (MD = -7.75, 95% CI: -13.48, -2.0, p=0.008). No significant effects were observed regarding the levels of high-density lipoprotein cholesterol and triglycerides. Significance In conclusion, this meta-analysis indicates that VPA therapy causes a decrease in the levels of total cholesterol and low-density lipoprotein cholesterol.